Global Survey Reveals More Than A Quarter Of Canadians With Type 2 Diabetes Do Not Take Insulin As Prescribed And One Third Are Experiencing Events Of Low Blood Sugar Frequently
One in five Canadian patients deliberately do not take insulin as prescribed to reduce the risk of experiencing low blood sugar at night
TORONTO, Nov. 28, 2012 /CNW/ - More than a quarter of Canadians living with type 2 diabetes are not taking insulin as prescribed by their physician, reveals an international survey. The survey reveals a startling correlation between mis-dosed insulin and incidences of dangerously low blood sugar, known as a hypoglycemic event, as one third of survey respondents also reported experiencing at least one hypoglycemic event over a 30-day period.
The GAPP2™ (Global Attitude of Patients and Physicians) survey shows that Canadian healthcare professionals (HCPs) are concerned that patients often under-report frequency or severity of hypoglycemic events despite reporting that they discussed these events with approximately six in ten patients over a 30-day time period.
Insulin dosing irregularities are common in Canadian patients The GAPP2™ survey revealed that HCPs believe that long acting insulin analogues are better than intermediate acting insulin (neutral protamine Hagedorn or NPH) in providing good blood glucose control and reducing hypoglycemia. However, insulin management still has some challenges which can result in the patients' diabetes not being well controlled:
- Long acting insulin dosing irregularities and self-treated hypoglycemia are common in type 2 diabetes patients who take insulin, and impact on the patients' well-being
- Patients' lives are negatively affected by having to take long acting insulin at the prescribed time, and taking long acting insulin at the same time each day is often inconvenient
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
TheStreet Quant Ratings
TRY IT FREENew! $49.95/yr
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Product Features:
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Dividend Stock Advisor
TRY IT FREEJim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
